AY
Ayurcann Holdings Corp.
AYURF · OTC
$0.00 +0.00% (+$0.00)
Market Cap $80.8K
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$0
100.0% downside
Current Price
$0.0003
Undervalued Fair Value Overvalued
According to Bulios Fair Price, AYURF is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
4/9Valuation
100 /100
Cheap P/S 0.00x
P/FCF 0.13x
P/E N/A
Growth
100 /100
Growing Rev. growth 49.10%
EPS growth N/A
FCF growth N/A
Profitability
17 /100
Weak Gross margin 30.78%
Net margin 11.72%
Op. margin 9.82%
Quality
79 /100
Excellent ROIC 83.79%
ROA 41.42%
Asset turnover 3.53x
Debt
1 /100
High Current ratio 0.44x
Int. coverage -5.16x
Debt/Equity N/A
Stability
15 /100
Unstable Beta 2.64x
Rev. volatility 42.42%
EPS volatility 43.23%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about AYURF
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Igal Sudman
Employees
5
Headquarters
Pickering
Upcoming events
02 NOV
Earnings
Upcoming earnings report